Abstract
Background: Major depressive disorder (MDD) is moderately heritable, with a high prevalence and a presumed high heterogeneity. Copy number variants (CNVs) could contribute to the heritable component of risk, but the two previous genome-wide association studies of rare CNVs did not report significant findings. Methods: In this meta-analysis of four cohorts (5780 patients and 6626 control subjects), we analyzed the association of MDD to 1) genome-wide burden of rare deletions and duplications, partitioned by length (<100 kb or >100 kb) and other characteristics, and 2) individual rare exonic CNVs and CNV regions. Results: Patients with MDD carried significantly more short deletions than control subjects (p = .0059) but not long deletions or short or long duplications. The confidence interval for long deletions overlapped with that for short deletions, but long deletions were 70% less frequent genome-wide, reducing the power to detect increased burden. The increased burden of short deletions was primarily in intergenic regions. Short deletions in cases were also modestly enriched for high-confidence enhancer regions. No individual CNV achieved thresholds for suggestive or significant association after genome-wide correction. p values < .01 were observed for 15q11.2 duplications (TUBGCP5, CYFIP1, NIPA1, and NIPA2), deletions in or near PRKN or MSR1, and exonic duplications of ATG5. Conclusions: The increased burden of short deletions in patients with MDD suggests that rare CNVs increase the risk of MDD by disrupting regulatory regions. Results for longer deletions were less clear, but no large effects were observed for long multigenic CNVs (as seen in schizophrenia and autism). Further studies with larger sample sizes are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 1065-1073 |
Number of pages | 9 |
Journal | Biological psychiatry |
Volume | 85 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2019 |
Keywords
- Copy number variation
- Genetics
- Genome-wide association study
- Major depressive disorder
- Meta-analysis
- Neuroscience
ASJC Scopus subject areas
- Biological Psychiatry
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biological psychiatry, Vol. 85, No. 12, 15.06.2019, p. 1065-1073.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts
AU - Zhang, Xianglong
AU - Abdellaoui, Abdel
AU - Rucker, James
AU - de Jong, Simone
AU - Potash, James B.
AU - Weissman, Myrna M.
AU - Shi, Jianxin
AU - Knowles, James A.
AU - Pato, Carlos
AU - Pato, Michele
AU - Sobell, Janet
AU - Smit, Johannes H.
AU - Hottenga, Jouke Jan
AU - de Geus, Eco J.C.
AU - Lewis, Cathryn M.
AU - Buttenschøn, Henriette N.
AU - Craddock, Nick
AU - Jones, Ian
AU - Jones, Lisa
AU - McGuffin, Peter
AU - Mors, Ole
AU - Owen, Michael J.
AU - Preisig, Martin
AU - Rietschel, Marcella
AU - Rice, John P.
AU - Rivera, Margarita
AU - Uher, Rudolf
AU - Gejman, Pablo V.
AU - Sanders, Alan R.
AU - Boomsma, Dorret
AU - Penninx, Brenda W.J.H.
AU - Breen, Gerome
AU - Levinson, Douglas F.
N1 - Funding Information: For the Molecular Genetics of Schizophrenia (MGS) control cohort from which GenRED-I controls were drawn: This work was supported primarily by the National Institutes of Health (Grant Nos. R01MH067257 [to NG Buccola], R01MH 059588 [to BJ Mowry], R01MH059571 [to PVG], R01MH059565 to [R Freedman], R01MH059587 [to F Amin], R01MH060870 [to WF Byerley], R01M H059566 [to DW Black], R01MH059586 [to JM Silverman], R01MH061675 [to DFL], R01MH060879 to [CR Cloninger], R01MH081800 [to PVG], U01MH046276 to [CR Cloninger], U01MH046289 [to C Kaufmann], U01MH046318 [to MT Tsuang], U01MH079469 to [PVG], and U01MH079470 to [DFL]), the Genetic Association Information Network (GAIN, for genotyping of half of the EA sample), and The Paul Michael Donovan Charitable Foundation . Genotyping was carried out by the Center for Genotyping and Analysis at the Broad Institute of Harvard and MIT (to S Gabriel and DB Mirel), supported by NIH Grant No. U54RR020278 . We are grateful to Knowledge Networks (Menlo Park, CA) for assistance in collecting the control data set. Funding Information: NESDA/NTR: The Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR) contributed to GAIN-MDD and to MDD2000. Funding was from: the Netherlands Organization for Scientific Research (MagW/ZonMW Grants 904-61-090, 985-10002 , 904-61-193 , 480-04-004 , 400-05-717 , 912-100-20 ; Spinozapremie 56-464-14192; Geestkracht program Grant 10-000-1002 ); the Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, VU University’s Institutes for Health and Care Research and Neuroscience Campus Amsterdam, NBIC/BioAssist/ RK (2008.024); the European Science Foundation (EU/QLRT-2001-01254); the European Community’s Seventh Framework Program (FP7/2007-2013); ENGAGE (HEALTH-F4-2007-201413); and the European Science Council (ERC, 230374). Genotyping was funded in part by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH (MH081802). CM Middeldorp was supported by the Netherlands Organization for Scientific Research (NOW-VENI grant 916-76-125 ). Funding Information: GenRED and GenRED II: These projects were supported by National Institute of Mental Health ( NIMH) R01 Grants MH061686 (to DFL), MH059542 (to WH Coryell), MH075131 (to WB Lawson), MH059552 (to JBP), MH059541 (to WA Scheftner) and MH060912 (to MMW). The NIMH Cell Repository at Rutgers University and the NIMH Center for Collaborative Genetic Studies on Mental Disorders made essential contributions to this project. Genotyping was carried out by the Broad Institute Center for Genotyping and Analysis with support from Grant U54 RR020278 (which partially subsidized the genotyping of the GenRED cases). Collection and quality control analyses of the control data set were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression . Funding Information: GenRED and GenRED II: These projects were supported by National Institute of Mental Health (NIMH) R01 Grants MH061686 (to DFL), MH059542 (to WH Coryell), MH075131 (to WB Lawson), MH059552 (to JBP), MH059541 (to WA Scheftner) and MH060912 (to MMW). The NIMH Cell Repository at Rutgers University and the NIMH Center for Collaborative Genetic Studies on Mental Disorders made essential contributions to this project. Genotyping was carried out by the Broad Institute Center for Genotyping and Analysis with support from Grant U54 RR020278 (which partially subsidized the genotyping of the GenRED cases). Collection and quality control analyses of the control data set were supported by grants from NIMH and the National Alliance for Research on Schizophrenia and Depression. For the Molecular Genetics of Schizophrenia (MGS) control cohort from which GenRED-I controls were drawn: This work was supported primarily by the National Institutes of Health (Grant Nos. R01MH067257 [to NG Buccola], R01MH 059588 [to BJ Mowry], R01MH059571 [to PVG], R01MH059565 to [R Freedman], R01MH059587 [to F Amin], R01MH060870 [to WF Byerley], R01M H059566 [to DW Black], R01MH059586 [to JM Silverman], R01MH061675 [to DFL], R01MH060879 to [CR Cloninger], R01MH081800 [to PVG], U01MH046276 to [CR Cloninger], U01MH046289 [to C Kaufmann], U01MH046318 [to MT Tsuang], U01MH079469 to [PVG], and U01MH079470 to [DFL]), the Genetic Association Information Network (GAIN, for genotyping of half of the EA sample), and The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Center for Genotyping and Analysis at the Broad Institute of Harvard and MIT (to S Gabriel and DB Mirel), supported by NIH Grant No. U54RR020278. We are grateful to Knowledge Networks (Menlo Park, CA) for assistance in collecting the control data set. NESDA/NTR: The Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Register (NTR) contributed to GAIN-MDD and to MDD2000. Funding was from: the Netherlands Organization for Scientific Research (MagW/ZonMW Grants 904-61-090, 985-10002, 904-61-193, 480-04-004, 400-05-717, 912-100-20; Spinozapremie 56-464-14192; Geestkracht program Grant 10-000-1002); the Center for Medical Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure, VU University's Institutes for Health and Care Research and Neuroscience Campus Amsterdam, NBIC/BioAssist/ RK (2008.024); the European Science Foundation (EU/QLRT-2001-01254); the European Community's Seventh Framework Program (FP7/2007-2013); ENGAGE (HEALTH-F4-2007-201413); and the European Science Council (ERC, 230374). Genotyping was funded in part by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the NIMH (MH081802). CM Middeldorp was supported by the Netherlands Organization for Scientific Research (NOW-VENI grant 916-76-125). RADIANT: This work was supported by a joint grant from the United Kingdom Medical Research Council and GlaxoSmithKline (Grant No. G0701420) and the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and Institute of Psychiatry, King's College London. This work presents independent research in part funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work was also supported by the Wellcome Trust Grant No. 086635 (JJHR); NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London (SC-W); a Marie Curie Intra-European Fellowship within the 7th European Community Framework Programme; European Commission Grant Agreement No. 115008); and Canada Research Chairs program (http://www.chairs-chaires.gc.ca/). The Genome Based Therapeutic Drugs for Depression study was funded by a European Commission Framework 6 grant, European Commission Contract Reference LSHB-CT-2 003-503428, and GlaxoSmithKline. Genotyping was performed at the Centre Nationale De Genotypage, Evry, Paris. We acknowledge the contribution of phase 2 of the Wellcome Trust Case Control Consortium in providing access to control datasets from the 1958 British birth cohort and the National Blood Service cohort. We thank Stephan Sanders from the University of California at San Francisco for his assistance using CNVision. We also thank the individuals who participated in these projects and to the many clinicians who facilitated or contributed to them. Availability of Data and Biomaterials: Biomaterials and clinical data are available from the NIMH repository (https://nimhgenetics.org) for the GenRED cases (the GenRED1 cohort includes the family-based linkage cohort and part of the subsequent case collection; the GenRED2 cohort includes the remainder of the case collection); for the MGS controls; and for Genomic Psychiatry Cohort controls, including the Mayo Clinic controls. The authors report no biomedical financial interests or potential conflicts of interest. Funding Information: RADIANT: This work was supported by a joint grant from the United Kingdom Medical Research Council and GlaxoSmithKline (Grant No. G0701420 ) and the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and Institute of Psychiatry, King’s College London. This work presents independent research in part funded by the NIHR . The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. This work was also supported by the Wellcome Trust Grant No. 086635 (JJHR); NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King’s College London (SC-W); a Marie Curie Intra-European Fellowship within the 7th European Community Framework Programme; European Commission Grant Agreement No. 115008 ); and Canada Research Chairs program ( http://www.chairs-chaires.gc.ca/ ). The Genome Based Therapeutic Drugs for Depression study was funded by a European Commission Framework 6 grant, European Commission Contract Reference LSHB-CT-2 003-503428, and GlaxoSmithKline. Genotyping was performed at the Centre Nationale De Genotypage, Evry, Paris. We acknowledge the contribution of phase 2 of the Wellcome Trust Case Control Consortium in providing access to control datasets from the 1958 British birth cohort and the National Blood Service cohort. Publisher Copyright: © 2019 Society of Biological Psychiatry
PY - 2019/6/15
Y1 - 2019/6/15
N2 - Background: Major depressive disorder (MDD) is moderately heritable, with a high prevalence and a presumed high heterogeneity. Copy number variants (CNVs) could contribute to the heritable component of risk, but the two previous genome-wide association studies of rare CNVs did not report significant findings. Methods: In this meta-analysis of four cohorts (5780 patients and 6626 control subjects), we analyzed the association of MDD to 1) genome-wide burden of rare deletions and duplications, partitioned by length (<100 kb or >100 kb) and other characteristics, and 2) individual rare exonic CNVs and CNV regions. Results: Patients with MDD carried significantly more short deletions than control subjects (p = .0059) but not long deletions or short or long duplications. The confidence interval for long deletions overlapped with that for short deletions, but long deletions were 70% less frequent genome-wide, reducing the power to detect increased burden. The increased burden of short deletions was primarily in intergenic regions. Short deletions in cases were also modestly enriched for high-confidence enhancer regions. No individual CNV achieved thresholds for suggestive or significant association after genome-wide correction. p values < .01 were observed for 15q11.2 duplications (TUBGCP5, CYFIP1, NIPA1, and NIPA2), deletions in or near PRKN or MSR1, and exonic duplications of ATG5. Conclusions: The increased burden of short deletions in patients with MDD suggests that rare CNVs increase the risk of MDD by disrupting regulatory regions. Results for longer deletions were less clear, but no large effects were observed for long multigenic CNVs (as seen in schizophrenia and autism). Further studies with larger sample sizes are warranted.
AB - Background: Major depressive disorder (MDD) is moderately heritable, with a high prevalence and a presumed high heterogeneity. Copy number variants (CNVs) could contribute to the heritable component of risk, but the two previous genome-wide association studies of rare CNVs did not report significant findings. Methods: In this meta-analysis of four cohorts (5780 patients and 6626 control subjects), we analyzed the association of MDD to 1) genome-wide burden of rare deletions and duplications, partitioned by length (<100 kb or >100 kb) and other characteristics, and 2) individual rare exonic CNVs and CNV regions. Results: Patients with MDD carried significantly more short deletions than control subjects (p = .0059) but not long deletions or short or long duplications. The confidence interval for long deletions overlapped with that for short deletions, but long deletions were 70% less frequent genome-wide, reducing the power to detect increased burden. The increased burden of short deletions was primarily in intergenic regions. Short deletions in cases were also modestly enriched for high-confidence enhancer regions. No individual CNV achieved thresholds for suggestive or significant association after genome-wide correction. p values < .01 were observed for 15q11.2 duplications (TUBGCP5, CYFIP1, NIPA1, and NIPA2), deletions in or near PRKN or MSR1, and exonic duplications of ATG5. Conclusions: The increased burden of short deletions in patients with MDD suggests that rare CNVs increase the risk of MDD by disrupting regulatory regions. Results for longer deletions were less clear, but no large effects were observed for long multigenic CNVs (as seen in schizophrenia and autism). Further studies with larger sample sizes are warranted.
KW - Copy number variation
KW - Genetics
KW - Genome-wide association study
KW - Major depressive disorder
KW - Meta-analysis
KW - Neuroscience
UR - http://www.scopus.com/inward/record.url?scp=85063186192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063186192&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2019.02.022
DO - 10.1016/j.biopsych.2019.02.022
M3 - Article
C2 - 31003785
AN - SCOPUS:85063186192
SN - 0006-3223
VL - 85
SP - 1065
EP - 1073
JO - Biological psychiatry
JF - Biological psychiatry
IS - 12
ER -